Literature DB >> 10590312

Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid.

G Elad1, A Paz, R Haklai, D Marciano, A Cox, Y Kloog.   

Abstract

Ras proteins regulate cell growth, differentiation and apoptosis. Their activities depend on their anchorage to the inner surface of the plasma membrane, which is promoted by their common carboxy-terminal S-farnesylcysteine and either a stretch of lysine residues (K-Ras 4B) or S-palmitoyl moieties (H-Ras, N-Ras and K-Ras 4A). We previously demonstrated dislodgment of H-Ras from EJ cell membranes by S-trans,trans-farnesylthiosalicylic acid (FTS), and proposed that FTS disrupts the interactions between the S-prenyl moiety of Ras and the membrane anchorage domains. In support of this hypothesis, we now show that FTS, which is not a farnesyltransferase inhibitor, inhibits growth of NIH3T3 cells transformed by the non-palmitoylated K-Ras 4B(12V) or by its farnesylated, but unmethylated, K-Ras 4B(12) CVYM mutant. The growth-inhibitory effects of FTS followed the dislodgment and accelerated degradation of K-Ras 4B(12V), leading in turn to a decrease in its amount in the cells and inhibition of MAPK activity. FTS did not affect the rate of degradation of the K-Ras 4B, SVIM mutant which is not modified post-translationally, suggesting that only farnesylated Ras isoforms are substrates for facilitated degradation. The putative Ras-recognition sites (within domains in the cell membrane) appear to tolerate both C(15) and C(20) S-prenyl moeities, since geranylgeranyl thiosalicylic acid mimicked the growth-inhibitory effects of FTS in K-Ras 4B(12V)-transformed cells and FTS inhibited the growth of cells transformed by the geranylgeranylated K-Ras 4B(12V) CVIL isoform. The results suggest that FTS acts as a domain-targeted compound that disrupts Ras-membrane interactions. The fact that FTS can target K-Ras 4B(12V), which is insensitive to inhibition by farnesyltransfarase inhibitors, suggests that FTS may target Ras (and other prenylated proteins important for transformed cell growth) in an efficient manner that speaks well for its potential as an anticancer therapeutic agent.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10590312     DOI: 10.1016/s0167-4889(99)00144-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  23 in total

Review 1.  Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?

Authors:  Adrienne D Cox; Channing J Der; Mark R Philips
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

2.  Rapamycin and mTOR kinase inhibitors.

Authors:  Lisa M Ballou; Richard Z Lin
Journal:  J Chem Biol       Date:  2008-05-15

3.  Ras nanoclusters: a new drug target?

Authors:  Kwang-Jin Cho; John F Hancock
Journal:  Small GTPases       Date:  2013-01-01

4.  IgM-mediated autoimmune responses directed against anchorage epitopes are greater in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) than in major depression.

Authors:  Michael Maes; Ivana Mihaylova; Marta Kubera; Jean-Claude Leunis; Frank N M Twisk; Michel Geffard
Journal:  Metab Brain Dis       Date:  2012-05-22       Impact factor: 3.584

5.  Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer.

Authors:  Lisa Maria Mustachio; Yun Lu; Laura J Tafe; Vincent Memoli; Jaime Rodriguez-Canales; Barbara Mino; Pamela Andrea Villalobos; Ignacio Wistuba; Hiroyuki Katayama; Samir M Hanash; Jason Roszik; Masanori Kawakami; Kwang-Jin Cho; John F Hancock; Fadzai Chinyengetere; Shanhu Hu; Xi Liu; Sarah J Freemantle; Ethan Dmitrovsky
Journal:  Mol Cancer Res       Date:  2017-02-27       Impact factor: 5.852

6.  Disruption of actin filaments and suppression of pancreatic cancer cell viability and migration following treatment with polyisoprenylated cysteinyl amides.

Authors:  Augustine T Nkembo; Olufisayo Salako; Rosemary A Poku; Felix Amissah; Elizabeth Ntantie; Hernan Flores-Rozas; Nazarius S Lamango
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

7.  K-ras 4A and 4B mRNA levels correlate with superoxide in lung adenocarcinoma cells, while at the protein level, only mutant K-ras 4A protein correlates with superoxide.

Authors:  Richard J Calvert; Meghana Gupta; Anna Maciag; Yih-Horng Shiao; Lucy M Anderson
Journal:  Lung Cancer       Date:  2013-03-06       Impact factor: 5.705

8.  Determination of salirasib (S-trans,trans-farnesylthiosalicylic acid) in human plasma using liquid chromatography-tandem mass spectrometry.

Authors:  Ming Zhao; Ping He; Linping Xu; Manuel Hidalgo; Dan Laheru; Michelle A Rudek
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-05-22       Impact factor: 3.205

Review 9.  Treatment concepts for elderly patients with acute myeloid leukemia.

Authors:  Wolfgang R Sperr; Alexander W Hauswirth; Friedrich Wimazal; Paul Knöbl; Klaus Geissler; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

10.  Fendiline inhibits K-Ras plasma membrane localization and blocks K-Ras signal transmission.

Authors:  Dharini van der Hoeven; Kwang-jin Cho; Xiaoping Ma; Sravanthi Chigurupati; Robert G Parton; John F Hancock
Journal:  Mol Cell Biol       Date:  2012-11-05       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.